View by Specialty

Trending

PC0924Jennings_Graphic_01_WEB
October 01, 2024
2 min read
Save

Tea, red wine among foods tied to lower risk for dementia

Neurology News

SPONSORED CONTENT
Save
SPONSORED CONTENT
April 27, 2022
2 min read
Save

Ganaxolone reduces seizure frequency in patients with CDKL5 deficiency disorder

Ganaxolone reduces seizure frequency in patients with CDKL5 deficiency disorder

Ganaxolone was generally well tolerated and significantly reduced the frequency of seizures associated with CDKL5 deficiency disorder, according to a study published in The Lancet Neurology.

SPONSORED CONTENT
April 26, 2022
2 min read
Save

Familial hypercholesterolemia, long-term statin use not linked to risk for dementia

Familial hypercholesterolemia, long-term statin use not linked to risk for dementia

People with familial hypercholesterolemia and those on long-term, high-intensity statins had no greater risk for dementia than matched controls, per a study published in JAMA Network Open.

Trending

PC0924Jennings_Graphic_01_WEB
October 01, 2024
2 min read
Save

Tea, red wine among foods tied to lower risk for dementia

SPONSORED CONTENT
April 26, 2022
2 min read
Save

CAR-T effective, safe for certain patients with central nervous system-involved lymphoma

CAR-T effective, safe for certain patients with central nervous system-involved lymphoma

SALT LAKE CITY — Chimeric antigen receptor T-cell therapy appeared effective for patients with primary or secondary central nervous system large B-cell lymphoma, according to study results.

SPONSORED CONTENT
April 25, 2022
1 min read
Save

Benefits of ticagrelor, aspirin for stroke outweigh risks over 30 days

Benefits of ticagrelor, aspirin for stroke outweigh risks over 30 days

The benefits of ticagrelor and aspirin outweighed the risk for major hemorrhage in patients with mild to moderate ischemic stroke or at high risk for transient ischemic attack during 30 days of treatment, according to a Neurology study.

SPONSORED CONTENT
April 25, 2022
6 min read
Save

Q&A: Electronic health records bring 'extraordinary opportunities' for care

Q&A: Electronic health records bring 'extraordinary opportunities' for care

Satisfaction and support for electronic health records were significantly higher among physicians working in physician-owned practices than those in non-physician-owned practices, according to findings published in JAMA Network Open.

SPONSORED CONTENT
April 24, 2022
1 min read
Save

Neurodevelopment in infants with CHD may be predicted in utero

DENVER — Selective impairments in regional fetal brain growth predicted adverse development among infants with congenital heart disease, according to study findings presented at the Pediatric Academic Societies Meeting.

SPONSORED CONTENT
April 22, 2022
1 min read
Save

App-based mental exercises improve cognitive impairment

App-based mental exercises improve cognitive impairment

Those with amnestic mild cognitive impairment who used the BrainHQ app for visual speed and attention exercises improved neuropsychological measures of speed, attention, memory and connectivity.

SPONSORED CONTENT
April 22, 2022
1 min read
Save

FDA grants breakthrough device designation for MS plasma test

FDA grants breakthrough device designation for MS plasma test

The FDA has granted breakthrough device designation to Quanterix Corp. for its Simoa neurofilament light chain plasma test, a prognostic aid that assesses risk for disease activity in patients with relapsing-remitting MS.

SPONSORED CONTENT
April 22, 2022
2 min read
Save

HHS, White House announce new initiative to reduce emissions in health care

HHS, White House announce new initiative to reduce emissions in health care

In celebration of Earth Day, HHS, in partnership with the White House, has announced a pledge initiative calling for reduced emissions across the health care sector.

SPONSORED CONTENT
April 22, 2022
1 min read
Save

Phase 2 trial shows promising results for oral Parkinson’s treatment

Phase 2 trial shows promising results for oral Parkinson’s treatment

Neuroscience company Cerevance announced the completion of its phase 2 clinical trial of CVN424, a once-daily oral compound developed for the treatment of Parkinson’s disease.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails